CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy
The companies hosted a joint webcast on May 23, 2023, to discuss the transaction.
| Programs | Indications | Preclinical | IND Enabling Activities | Phase 1 | Phase 2 | Global Rights |
|---|---|---|---|---|---|---|
| CB4211 | NASH |
Preclinical Phase complete
|
IND Enabling Activities Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
 |
| Obesity |
Preclinical Phase complete
|
IND Enabling Activities Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
|
|
| CB5138 Analogs | IPF, Fibrotic Diseases |
Preclinical Phase in progress
|
IND Enabling Activities Phase not started
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
|
The first analog from our technology platform to be tested in humans.
View Program
View our posters and white papers regarding our research and science.
View Publications